Biogen MA Inc. v. EMD Serono, Inc., No. 19-1133 (Fed. Cir. Sept. 28, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal arises from a suit filed by Biogen MA, Inc. (“Biogen”) against EMD Serono, Inc. and Pfizer, Inc. ( col- lectively “Serono”) in the District of New Jersey.1 The suit alleged contributory and induced infringement of Biogen’s U.S. Patent Number 7,588,755 (“’755 patent”) by the sale and marketing in the United States of Rebif, a recombinant interferon-β (“ IFN-β”) product used for the treatment of Multiple Sclerosis (“MS”).